Abstract: In the rapidly evolving landscape of Internet of Vehicles (IoV) technology, cellular vehicle-to-everything (C-V2X) communication has attracted much attention due to its superior performance ...
The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback